515 First de-escalation chemotherapy study in ovarian cancer (OC): non-inferiority study of niraparib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completely debulked advanced ‘HRD-positive’ high-grade first-line OC patients